Tumor cell hypoxia and the hypoxia-response signaling system as a target for prostate cancer therapy

被引:9
作者
Anastasiadis, AG
Bemis, DL
Stisser, BC
Salomon, L
Ghafar, MA
Buttyan, R
机构
[1] Columbia Univ Coll Phys & Surg, Mol Urol Lab, Dept Urol, New York, NY 10032 USA
[2] Columbia Univ Coll Phys & Surg, Mol Urol Lab, Dept Pathol, New York, NY 10032 USA
关键词
prostate cancer; hypoxia; hypoxia inducible factor-1 alpha (HIF-1 alpha) angiogenesis; VEGF; apoptosis; Akt/protein kinase B;
D O I
10.2174/1389450033491136
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The accumulation of cancerous cells within a growing prostate tumor can deprive them of adequate vascular support. Without this support, the affected tumor cells become hypoxic, a condition that is usually unfavorable for the further growth and survival of eukaryotic cells. Mammalian cells, however, have the ability of responding to a hypoxic environment by activating a "hypoxia-response" signaling system. Ultimately, this signaling system upregulates the expression of a network of gene products that increase the propensity of the cell to survive even in this adverse environment. With increasing evidence that hypoxia and an activated hypoxia-response signaling system can influence progression (via increased angiogenic propensity and apoptotic resistance) and the therapeutic responsiveness of prostate cancer cells, this review will examine the concept of targeting hypoxia or the hypoxia-response system of prostate tumor cells as a means to suppress prostate tumor progression and metastasis or perhaps even as a means for eliminating prostate tumors in advanced prostate cancer patients.
引用
收藏
页码:191 / 196
页数:6
相关论文
共 54 条
[1]   Hypoxia induces the activation of the phosphatidylinositol 3-kinase/Akt cell survival pathway in PC12 cells -: Protective role in apoptosis [J].
Alvarez-Tejado, M ;
Naranjo-Suárez, S ;
Jiménez, C ;
Carrera, AC ;
Landázuri, MO ;
del Peso, L .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (25) :22368-22374
[2]   Human hormone-refractory prostate cancers can harbor mutations in the 02-dependent degradation domain of hypoxia inducible factor-1α (HIF-1α) [J].
Anastasiadis, AG ;
Ghafar, MA ;
Salomon, L ;
Vacherot, F ;
Benedit, P ;
Chen, MW ;
Shabsigh, A ;
Burchardt, M ;
Chopin, DK ;
Shabsigh, R ;
Buttyan, R .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2002, 128 (07) :358-362
[3]   CHEMOTHERAPY OF HORMONE-REFRACTORY CARCINOMA OF PROSTATE WITH 5-FLUOROURACIL, ADRIAMYCIN, AND MITOMYCIN-C [J].
BABAIAN, RJ ;
HSU, SD .
UROLOGY, 1984, 23 (03) :272-275
[4]   Exploring the mechanistic aspects of mitomycin antibiotic bioactivation in Chinese hamster ovary cells overexpressing NADPH:cytochrome C (P-450) reductase and DT-diaphorase [J].
Belcourt, MF ;
Hodnick, WF ;
Rockwell, S ;
Sartorelli, AC .
ADVANCES IN ENZYME REGULATION, VOL 38, 1998, 38 :111-133
[5]   Hypoxia:: the tumor's gateway to progression along the angiogenic pathway [J].
Brahimi-Horn, C ;
Berra, E ;
Pouysségur, J .
TRENDS IN CELL BIOLOGY, 2001, 11 (11) :S32-S36
[6]   Hypoxia-specific cytotoxins in cancer therapy [J].
Brown, JM ;
Sum, BG .
SEMINARS IN RADIATION ONCOLOGY, 1996, 6 (01) :22-36
[7]  
BUSH RS, 1978, BRIT J CANCER, V37, P302
[8]  
Buttyan R, 2000, Curr Opin Urol, V10, P415, DOI 10.1097/00042307-200009000-00009
[9]   Role of HIF-1α or in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis [J].
Carmeliet, P ;
Dor, Y ;
Herbert, JM ;
Fukumura, D ;
Brusselmans, K ;
Dewerchin, M ;
Neeman, M ;
Bono, F ;
Abramovitch, R ;
Maxwell, P ;
Koch, CJ ;
Ratcliffe, P ;
Moons, L ;
Jain, RK ;
Collen, D ;
Keshet, E .
NATURE, 1998, 394 (6692) :485-490
[10]   A dominant-negative isoform lacking exons 11 and 12 of the human hypoxia-inducible factor-1α gene [J].
Chun, YS ;
Choi, E ;
Kim, TY ;
Kim, MS ;
Park, JW .
BIOCHEMICAL JOURNAL, 2002, 362 (01) :71-79